Search
Gyre Therapeutics Inc
GYREAdd to Watchlist
4.310USD
+0.010+0.23%
Close 11-13 16:00（ET）
456.99MMarket Cap
LossP/E TTM
Gyre Therapeutics Inc (GYRE) Stock Price Target & Forecast
Analyst Rating
Based on 3 analysts giving stock ratings to Gyre Therapeutics Inc in the past month.
Buy
1 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
18.667USD+309.81%
GYRE Analyst Recommendation Trends
In the current month, GYRE has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GYRE average Analyst price target in the last month is 18.667.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
3
3
3
3
3
3
GYRE Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, GYRE EPS is projected to reach -0.125 in FY2026Q4, following reported EPS of -0.038 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.07
-0.09
-0.13
-0.13
Actual
-0.10
-0.12
-0.04
--
Surprise
-29.78%
-28.77%
+69.50%
--
FAQs
What is Gyre Therapeutics Inc's expected revenue for the next quarter?
Gyre Therapeutics Inc's expected revenue is 29.62M.
What is Gyre Therapeutics Inc's price target?
Analysts forecast that Gyre Therapeutics Inc's price target is USD 18.67, with the highest forecast at USD 20.00 and the lowest forecast at USD 18.00.
How have Gyre Therapeutics IncGYRE's recent earnings per share performed?
The market expectation was USD -0.04, while Gyre Therapeutics IncGYRE's earnings per share (EPS) for the previous quarter was USD -0.12. EPS for the next quarter is expected at USD -0.12.
What is the analyst rating for Gyre Therapeutics Inc?
Based on the ratings of Gyre Therapeutics Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.